Relay Therapeutics (RLAY) FCF Margin (2021 - 2026)
Relay Therapeutics (RLAY) posted quarterly FCF Margin of 1703.73% for Q1 2026, down 74535.0% year-over-year from N/an in Q1 2025, and down 165.82% quarter-over-quarter from 640.94% in Q4 2025.
Powered by 
Analysis
Relay Therapeutics (RLAY) FCF Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported FCF Margin for 6 consecutive years, with 1703.73% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 74535.0% year-over-year to 1703.73%; the TTM figure through Mar 2026 stood at 1998.53% (up 155162.0% YoY), while the FY2025 annual figure was 1536.08%, up 97341.0% from the prior year.
- FCF Margin slipped to 1703.73% in Q1 2026 per RLAY's latest filing, from 640.94% in the prior quarter.
- Across five years, FCF Margin topped out at 8930600.0% in Q4 2023 and bottomed at 58910.92% in Q2 2023.
- Historically, FCF Margin has averaged 673613.82% across 5 years, with a median of 8166.47% in 2025.
- On a YoY basis, FCF Margin climbed as much as 895407628 bps in 2023 and fell as far as 4276024 bps in 2023.
- Relay Therapeutics' FCF Margin stood at 23476.28% in 2022, then soared by 38141 bps to 8930600.0% in 2023, then sank by 100 bps to 520.67% in 2024, then dropped by 23 bps to 640.94% in 2025, then sank by 166 bps to 1703.73% in 2026.
- Business Quant data shows RLAY's FCF Margin at 1703.73% in Q1 2026, 640.94% in Q4 2025, and 8166.47% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Relay Therapeutics | 3.87 Bn | 3.87 Bn | - | -15,459.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15,459.71% |
| Mar 31, 2026 | -1,703.73% |
| Dec 31, 2025 | -640.94% |
| Jun 30, 2025 | -8,166.47% |
| Mar 31, 2025 | -958.38% |
| Mar 31, 2024 | -520.67% |
| Dec 31, 2023 | 8,930,600.00% |
| Sep 30, 2023 | -301.51% |
| Jun 30, 2023 | -58,910.92% |
| Mar 31, 2023 | -30,550.88% |
| Dec 31, 2022 | -23,476.28% |
| Sep 30, 2022 | -19,837.21% |
| Jun 30, 2022 | -16,150.68% |
| Mar 31, 2022 | -12,402.63% |
| Dec 31, 2021 | -7,158.20% |
| Sep 30, 2021 | -8,215.17% |
| Jun 30, 2021 | -3,405.33% |
| Mar 31, 2021 | 4,849.16% |